Waters Expands Cervical Cancer Screening Access with At-Home HPV Test Approval

Why It Matters

Home‑based HPV testing removes barriers to early detection, potentially boosting screening rates and reducing cervical cancer mortality. The clearance also positions Waters as a key player in the expanding molecular diagnostics market.

Key Takeaways

• FDA clears Onclarity HPV Self-Collection Kit for at-home use
• Kit detects all high‑risk HPV genotypes with individual and pooled results
• Samples processed on automated BD COR System, ensuring lab‑grade accuracy
• Prescription kits expected to be covered by insurance nationwide
• NCI‑Waters SHIP trial will validate self‑collection performance

Pulse Analysis

Cervical cancer remains the fourth most common cancer among women worldwide, yet screening adherence in the United States hovers around 70 percent. Traditional Pap smears require clinic visits, creating logistical and psychological hurdles that deter many eligible patients. The FDA’s clearance of the Onclarity HPV Self‑Collection Kit marks a pivotal shift, offering a clinically validated, at‑home alternative that aligns with the broader telehealth movement and could close the screening gap for underserved populations.

The approved kit pairs the BD Onclarity HPV Assay with the BD COR System, a fully automated platform that delivers high‑throughput, laboratory‑grade results from self‑collected samples. By detecting all high‑risk HPV genotypes and providing both individual and pooled data, the test meets the rigorous sensitivity and specificity standards required for primary screening. The ongoing SHIP trial, a collaboration between Waters and the National Cancer Institute, will further assess real‑world accuracy, bolstering clinician confidence and paving the way for broader adoption.

From a market perspective, the clearance unlocks a new revenue stream for Waters as it negotiates insurance coverage for prescription‑based kits. With the anticipated $17.5 billion BD‑Waters diagnostic merger on the horizon, this at‑home solution enhances the combined portfolio’s appeal to payers and providers seeking integrated, patient‑centric diagnostics. Increased screening uptake could translate into earlier interventions, lower treatment costs, and a measurable public‑health impact, reinforcing the strategic importance of this FDA approval for both the industry and patients.